# Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Study · id `cardio:ct-nct03907046` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03907046](<https://clinicaltrials.gov/study/NCT03907046>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03907046

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 700 participants.

## Technical summary

Registry record NCT03907046. Randomized; quadruple masking; primary purpose prevention. Start 2020-01-28 (actual); primary completion 2027-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 700 participants (planned count; ClinicalTrials.gov record NCT03907046, source copy `cardio:ctgov-nct03907046-2026-05-08`, retrieved 2026-10-26)
- Started: 2020-01-28 (actual) (ClinicalTrials.gov record NCT03907046, source copy `cardio:ctgov-nct03907046-2026-05-08`, retrieved 2026-10-26)
- Primary completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT03907046, source copy `cardio:ctgov-nct03907046-2026-05-08`, retrieved 2026-10-26)
- Completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT03907046, source copy `cardio:ctgov-nct03907046-2026-05-08`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03907046, source copy `cardio:ctgov-nct03907046-2026-05-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03907046-2026-05-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
- Acronym: ASPIRE
- Condition: Intracerebral Hemorrhage
- Condition: Atrial Fibrillation
- Intervention (Drug): Apixaban
- Intervention (Drug): Aspirin
- Lead sponsor: Yale University
- Lead sponsor class: OTHER
- Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Yale University (`cardio:org-yale-university`)
- Registry lists this organization as a collaborator: National Institute of Neurological Disorders and Stroke (`cardio:ninds`)

## Provenance

Content hash: 57f022cb084e11fa8cdc9a8eacdcb34d2d233b795cd12b813f0d12ba95cc6299
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
